临床阶段药物开发公司Incannex发布6月季度报告，6项药物试验同时进行
临床阶段药物开发公司Incannex Healthcare Limited (ASX: IHL)提供其截至2020年6月30日的季度活动报告和附录4C。IHL正在同时进行最终目标是通过美国食品和药物管理局 (FDA) 的6个项目，这些临床药物是注入大麻配方的候选要和致幻剂药物。此外，IHL宣布停止其大麻油的销售业务。
IHL
Incannex开始多用途候选药物IHL-675A 1期人体临床试验，国际专利审查员评论该治疗方法“新颖和创造性”
大麻素和致幻剂药物开发公司Incannex Healthcare Limited (ASX: IHL) 已启动1期人体临床试验，以评估其多用途候选药物IHL- 675A软胶囊的安全性。这项研究将在阿德莱德的CMAX临床研究中心进行，由澳大利亚临床研究组织 (CRO) Avance Clinical负责领导。
脱水简报 - Incannex Healthcare个股分析
Incannex Healthcare（ASX: IHL）是一家临床阶段的药物开发公司，为治疗广泛性焦虑症（GAD）、阻塞性睡眠呼吸暂停症（OSA）、创伤性脑损伤（TBI）/脑震荡和急性呼吸窘迫综合征（ARDS）开发独特的药用大麻药物和迷幻药物疗法。
Incannex就IHL-42X申请国际专利，并获批开始研究测试药物延长效用
临床阶段大麻素开发公司Incannex Healthcare Limited (ASX: IHL)今日宣布已就IHL- 42X (一种治疗阻塞性睡眠呼吸暂停 (OSA) 的候选药物) 提交国际专利申请，并已获得伦理批准将开始一项开放扩展研究。
Incannex (IHL) files international patent over IHL-42X and obtains ethics approval to extend delivery of the drug to patients in open label study
Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL) announced that it has lodged an international patent application over IHL-42X, a drug candidate to treat obstructive sleep apnoea (OSA) and has received ethics approval to commence an open-label extension study for the drug.
Incannex (ASX: IHL) engages Procaps to encapsulate its anti-inflammatory candidate IHL-675A
Incannex Healthcare Limited (ASX: IHL), a clinical stage pharmaceutical development company, announced the engagement of Procaps S.A. to develop the specific formulation and soft gel capsules of the company’s CBD-infused anti-inflammatory drug candidate IHL-675A.
Incannex (ASX: IHL) 与Procaps合作开发其抗炎候选药物IHL-675A的特定配方
临床阶段的药物开发公司Incannex Healthcare Limited (ASX: IHL) 今日宣布与Procaps S.A.合作，使用Procap的专有专利UniGel技术开发其大麻抗炎药物候选 IHL-675A的特定配方。
Incannex engaged inhalation drug formulation specialist Vectura to manufacture IHL-216A to be used in clinical trials
Incannex Healthcare Limited (ASX: IHL), an ASX-Listed cannabinoid and psychedelic medecine development company, announced that it has engaged drug manufacturer and developer Vectura Limited to develop the specific formulation for IHL-216A to be used in the pivotal clinical trials required for product registration.
大麻药物制药商Incannex Healthcare (IHL) 将确定治疗创伤性脑损伤的最终药物配方
澳交所上市的药物开发公司Incannex Healthcare Limited (ASX: IHL) 宣布已聘请药物制造商和开发商Vectura Limited共同开发IHL- 216A的特定配方，该配方将用于产品注册所需的关键临床试验。
Incannex Healthcare (IHL) partners with Sleep Research Centre at UWA to expand the IHL-42X OSA study program
Incannex Healthcare Limited (ASX: IHL), an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (‘OSA’).